前列腺癌骨活检组织基因组分析成功的临床、影像与技术因素
本研究分析2014至2018年间243例进展性转移性去势抵抗性前列腺癌(mCRPC)患者的269次骨活检,评估临床、影像和技术因素与大规模DNA测序成功的关联。多因素分析显示,FDG最大标准化摄取值较高、活检样本数较多和CT平均衰减较低与测序成功显著相关。
要点
- 269次骨活检中159次(59%)获得足够肿瘤材料进行基因组分析。
- 199例提交分子检测的mCRPC样本中159例(80%)获得基因组图谱。
- FDG最大标准化摄取值较高、活检样本数较多、CT平均衰减较低与测序成功独立相关。
核心结论
- 在mCRPC患者中,来自代谢活跃且CT衰减较低部位的骨活检与大规模DNA测序平台基因组分析成功率较高相关。
研究设计与样本
- 分析2014年至2018年间243例进展性mCRPC患者的269次骨活检,采用单因素和多因素分析评估临床、影像和技术因素与基因组分析成功的关联。
主要发现
- 269次活检中159次(59%)获得足够肿瘤材料进行基因组分析;70次(26%)组织病理学为mCRPC阴性,40次(15%)肿瘤不足。
- 199例提交分子检测的mCRPC样本中159例(80%)获得基因组图谱。
- 单因素分析显示PSA、血清酸性磷酸酶、活检样本数、FDG PET阳性、CT衰减和CT形态与基因组分析成功显著相关。
- 多因素分析显示FDG最大标准化摄取值较高(OR 7.51,95%CI 3.01-18.78;p<0.001)、活检样本数较多(OR 4.73,95%CI 1.49-15.02;p=0.008)和CT平均衰减较低(OR 0.4,95%CI 0.18-0.89;p=0.025)与测序成功显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The source of tissue for genomic profiling of metastatic castration-resistant prostate cancer (mCRPC) is often limited to osseous metastases. To guide patient management, metastatic site selection and the technique for targeted bone biopsies are critical for identifying deleterious gene mutations. Our objective was to identify key parameters associated with successful large-panel DNA sequencing. METHODS: We analyzed parameters for 243 men with progressing mCRPC who underwent 269 bone biopsies for genomic profiling between 2014 and 2018. Univariate and multivariate analyses were performed for clinical, imaging (bone scan; fluorodeoxyglucose [FDG] positron emission tomography [PET]; computed tomography [CT]; magnetic resonance imaging), and technical (biopsy site, number of samples, needle gauge) features associated with successful genomic profiling. KEY FINDINGS AND LIMITATIONS: Overall, 159 of 269 biopsies (59%) generated sufficient tumor material for a genomic profile. Seventy (26%) of the failures were histopathologically negative for mCRPC and 40 (15%) had insufficient tumor for genomic profiling. Of 199 mCRPC samples submitted for molecular testing, 159 (80%) yielded a genomic profile. On univariate analysis, PSA, serum acid phosphatase, number of biopsy samples, FDG PET positivity, CT attenuation, and CT morphology were significantly associated with genomic profiling success. On multivariate analysis, higher FDG maximum standardized uptake value (odds ratio [OR] 7.51, 95% confidence interval [CI] 3.01-18.78; p < 0.001), higher number of biopsy samples (OR 4.73, 95% CI 1.49-15.02; p = 0.008), and lower mean CT attenuation (OR 0.4, 95% CI 0.18-0.89; p = 0.025) were significantly associated with sequencing success. CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with mCRPC, bone biopsies from sites with metabolic activity and lower CT attenuation are associated with higher success rates for genomic profiling via a large-panel DNA sequencing platform. PATIENT SUMMARY: We identified factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer. Our findings may help in guiding the right scan technique and biopsy site for personalized treatment planning.
引用
- Ridouani F, Alberto Vargas H, Holzwanger DJ, et al. Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39095299. doi:10.1016/j.euo.2024.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。